Management of MRSA with glycopeptides: What are the limitations?;Prise en charge des infections à SARM par les glycopeptides: Quelles limites?

Antibiotiques

Volumn 6, Issue 1 II, 2004, Pages 79-82

  Beaucaire, G ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG USE; HEALTH CARE MANAGEMENT; HUMAN; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATIENT CARE; PRESCRIPTION; STAPHYLOCOCCUS INFECTION;

EID: 2642545115     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1294-5501(04)94244-6     Document Type: Article

References (38)

1. El Sohl N. Le point sur la résistance aux antibiotiques des staphylocoques. Antibiotiques 2000 ; 2 : 52-63.
2. Fluit AC, Wielders CL, Verhoef J, et al. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001 ; 39 : 3727-32.
3. Lepelletier D, Richet H. Surveillance and control of methicillin-resistant Staphylococcus aureus infections in French hospitals. Infect Control Hosp Epidemiol 2001 ; 22 : 677-82.
4. Ho PL, et al. for the Hong Kong intensive care unit antimicrobial resistance study (HK-ICARE) Group. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant Gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Crit Care Med 2003 ; 31: 1175-82.
5. Lucet JC, Chevret S, Durand-Zaleski I, et al. Multicenter Study Group. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 2003 ; 163 : 181-8.
6. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003 ; 24 : 451-5.
7. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003 ; 16 : 103-24. Review.
8. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003 ; 36 : 131-9.
9. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002 ; 35 : 819-24.
10. Slevert, et al. MWWR 2002.
11. Le Maitre N, Sougaroff W, Masmoudi A, et al. Characterization of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus involved in nosocomial spread. J Clin Microbiol 1998 ; 36 : 81-5.
12. Diekema DJ, Pfaller MA, Schmitz FJ, et al. SENTRY Partcipants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001 ; 32 : S114-32.
13. Rodriguez-Villalobos H, Struelens MJ, Jones RJ. Antimicrobial resistance rates of Staphylococcus aureus causing bloodstream infection and nosocomial pneumonia: a report from the Euro-Sentry Program 2000-2002. ICAAC 2003, Chicago, Abstract C2-1824.
14. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial inection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995 ; 274 : 639-44.
15. Carbonne A. Pour le réseau microbiologie du CCLIN Paris-Nord (hors AP-HP). Surveilance des bactéries multiré sistantes à partir du laboratoire. Bulletin du CClin Paris-Nord 2000, 4-5.
16. Diekema DJ, Pfaller MA, Turnidge J, et al. Genetic relatedness of multi-drug resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY antimicrobial resistance surveillance centers worldwide 1998, Microb Drug Resist 2000 : 213-21.
17. Melzer M, Eykin SJ, Grandsen WR, et al. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Inf Dis 2003 ; 37 : 1453-60.
18. Mongkolrattanothai K, Boyle S, Kahana MD, et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant Isolates. Clin Inf Dis 2003 ; 37 : 1050-8.
19. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003 ; 36 : 53-9.
20. Kim SH, Park WB, Lee KD, et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003 ; 37 : 794-9.
21. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003 ; 36 : 1418-23.
22. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002 ; 35 : 819-24.
23. Fridkin SK, Hageman J, McDougal LK, et al. Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003 ; 36 : 429-39.
24. Garrouste-Orgeas M, Timsit JF, Kallel H, et al. Colonization with methicillin-resistant Staphylococcus aureus in ICU patients: morbidity, mortality, and glycopeptide use. Infect Control Hosp Epidemiol 2001 ; 22 : 687-92.
25. Lepelletier D, Surveillance et contrôle des infections à Staphylococcus aureus résistants à la mé ticilline dans les hôpitaux français. BEH 2001 ; 6.
26. Greenwood D, Bidgood K, Turner M. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin. J Antimicrob Chemother 1987 ; 20 : 155-64.
27. Nagl M, Neher C, Hager J, et al. Bactericidal activity of vancomycin in cerebrospinal fluid. Antimicrob Agents Chemother 1999 ; 43 : 1932-4.
28. James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996 ; 40 : 696-700.
29. Brinquin L, Rousseau JM, Boulesteix G, et al. Continuous infusion of vancomycin in postneurosurgical staphylococcal meningitis in adults. Presse Med 1993 ; 22 : 1815-7.
30. Barois A, Estournet B, Moranne JB, et al. Ventricular staphylococcal infections. Treatment with vancomycin by continuous venous infusion. Presse Med 1986 ; 15 : 1805-8.
31. Sieradzki K, Roberts RB, Haber SW, et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. New England J Med 1999 ; 340 : 517-23.
32. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. New England J Med 1999 ; 340 : 493-501.
33. Wong SS, Ho PL, Woo PC, et al. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999 ; 29 : 760-7.
34. Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988 ; 32 : 1320-2.
35. Daschner FD, Kropec A. Glycopeptides in the treatment of staphylococcal infections. Eur J Clin Microbiol Infect Dis 1995 ; 14 : S12-7. Review.
36. Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997 ; 16 : 385-8.
37. Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 ; 45 : 329-35.
38. Fagon J, Patrick H, Haas DW, et al.Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000 ; 161 : 753-62. Erratum in: Am J Respir Crit Care Med 2001 ; 163 : 1759-60.